PURPOSE: Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma. METHODS: Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide. Both MRI and MET-PET were performed before treatment (baseline) and at 4 and 8 weeks after starting treatment. Results on MRI (response or nonresponse) were compared with those on MET-PET, with response defined as a tumor-to-normal brain ratio of SUV (SUVT/N) of less than 1.6. Progression-free survival (PFS) was compared between responders and nonresponders on MRI alone and MET-PET alone. Progression-free survival was also compared between patients showing response on both MRI and MET-PET and patients showing response on MRI but nonresponse on MET-PET at each time point. RESULTS: PFS was significantly longer in responders than nonresponders on both MRI at 4 and 8 weeks and MET-PET at 8 weeks, whereas MET-PET at 4 weeks provided no information regarding outcomes. Combined assessment with MRI and MET-PET at 4 weeks was not provide predictive of PFS, whereas patients showing response on both modalities (true responders) at 8 weeks exhibited significantly longer PFS than did patients showing response on MRI but nonresponse on MET-PET (pseudoresponders). CONCLUSIONS: Combined assessment with MRI and MET-PET at 8 weeks can differentiate true responders who are predicted to show more favorable prognosis from pseudoresponders.
PURPOSE: Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma. METHODS: Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide. Both MRI and MET-PET were performed before treatment (baseline) and at 4 and 8 weeks after starting treatment. Results on MRI (response or nonresponse) were compared with those on MET-PET, with response defined as a tumor-to-normal brain ratio of SUV (SUVT/N) of less than 1.6. Progression-free survival (PFS) was compared between responders and nonresponders on MRI alone and MET-PET alone. Progression-free survival was also compared between patients showing response on both MRI and MET-PET and patients showing response on MRI but nonresponse on MET-PET at each time point. RESULTS: PFS was significantly longer in responders than nonresponders on both MRI at 4 and 8 weeks and MET-PET at 8 weeks, whereas MET-PET at 4 weeks provided no information regarding outcomes. Combined assessment with MRI and MET-PET at 4 weeks was not provide predictive of PFS, whereas patients showing response on both modalities (true responders) at 8 weeks exhibited significantly longer PFS than did patients showing response on MRI but nonresponse on MET-PET (pseudoresponders). CONCLUSIONS: Combined assessment with MRI and MET-PET at 8 weeks can differentiate true responders who are predicted to show more favorable prognosis from pseudoresponders.
Authors: Cornelius Deuschl; Christoph Moenninghoff; Sophia Goericke; Julian Kirchner; Susanne Köppen; Ina Binse; Thorsten D Poeppel; Harald H Quick; Michael Forsting; Lale Umutlu; Ken Herrmann; Joerg Hense; Marc Schlamann Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-03 Impact factor: 9.236
Authors: Maya S Graham; Simone Krebs; Tejus Bale; Kwaku Domfe; Stephanie M Lobaugh; Zhigang Zhang; Mark P Dunphy; Thomas Kaley; Robert J Young Journal: Neurooncol Adv Date: 2020-04-15
Authors: Sean Miller; Pin Li; Matthew Schipper; Larry Junck; Morand Piert; Theodore S Lawrence; Christina Tsien; Yue Cao; Michelle M Kim Journal: Adv Radiat Oncol Date: 2019-09-07